The 2026 turning point (French “proxy board” and European “Industrial Accelerator Act”) Eutelsat, LMB, Exaion, Biogaran, Doliprane/Opella: France foreign direct investment (“FDI”) screening regime no longer merely authorizes or prohibits; it now secures the implementation of transactions through governance and shareholding remedies (golden share, board seat, entry into the capital of a public or French…

Preparing and Legally Securing the Transaction for Founders and Investors Fundraising for a French company always takes place within a structured legal framework: organizing capital, choosing financial instruments, preparing a credible business plan, and then negotiating with investors (funds, business angels, corporations, etc.). In concrete terms, fundraising involves: Preparing comprehensive documentation on the company, subsidiaries,…

Since 2023, M&A transactions involving companies established in the European Union have been subject to a new scrutiny, still unfamiliar to many international investors: the control of foreign subsidies introduced by Regulation (EU) 2022/2560, commonly known as the Foreign Subsidies Regulation (FSR). This text, which came into force on July 12, 2023, marks a milestone…

The sale of a controlling 50% stake in Opella, Sanofi’s €15 billion consumer healthcare subsidiary responsible for Doliprane, to the US investment fund Clayton, Dubilier & Rice (CD&R) has prompted a strategic response from the French state, and considerable controversy in France. Through Bpifrance, the French state would become a minority shareholder in Opella, holding…

Rimon Law is pleased to announce the arrival of attorneys Ricardo Ampudia, Christopher Kelly, Tyler Dolan and Walid Ghedira. “We are very excited to continue to expand the depth of our litigation, trusts and estates, and international practices, with the recruitment of Ricardo, Christopher, Tyler and Walid,” said Rimon Managing Partner, Juan Zúñiga.  “This group…